As the COVID-19 pandemic unfolds across the globe, there is an urgent need for data on the impact of the virus on people with MS who are almost universally exposed to therapies that suppress the immune system.
This project, led by Associate Professor Ingrid van der Mei, is using the well-established infrastructure of the Australian MS Longitudinal Study (AMSLS) to rapidly survey and record information on COVID-19 infection in people with MS, directly from the people with MS themselves. The surveys will take 5-10 minutes and can be completed online.
The survey aims to capture information from people with MS who have been infected and those who haven’t. This information will be used to understand if people with MS are at an increased risk of contracting the infection or if they do, whether their outcomes are worse. Since MS medications all impact the immune system differently, we also need to understand whether being on different MS treatments changes the risk or outcome of a COVID-19 infection.
The information collected in Australia will be contributed to an international data registry set up by the MS international Foundation (MSIF) and MS Data Alliance (MSDA). This study will also complement the clinical data being collected through the ANZAN COVID-19 in MS Registry.
The information from the AMSLS registry is particularly useful to the international data collection effort during COVID-19, because it also provides high-quality detailed data on people with MS who are not infected with COVID-19 for comparison.
People with MS who are interested in contributing to this study (whether they have COVID-19 or not), can contact the study investigators at AMSLS.email@example.com. Further information on the AMSLS can be found here: https://msra.org.au/amsls/.
Updated 1 July 2020
Updated: 07 October, 2020